NuProbe Global, a Houston, TX- and Shanghai, China-based genomics and molecular diagnostics company, raised $50M in funding.
The round was co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the round.
The funds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies.
Led by Yingshuang Chai, CEO, and David Zhang, Co-Founder of NuProbe Global and CEO of NuProbe USA, NuProbe Global is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. The company has sites in Houston, USA, Shanghai, China, and Suzhou, China.
Since last round of fundraising in 2021, the company has engaged in research collaborations with several multinational companies, as well as clinical collaborations with over 400 hospitals.